External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

SUO 2024

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Dec 4 / Roche and Genentech
Disease-free survival and overall survival in patients with high-risk muscle-invasive bladder cancer who have persistent circulating tumor DNA-negative biomarker status post-cystectomy: IMvigor011 study surveillance analysis
This poster reports DFS and OS outcomes in patients with high-risk MIBC who had persistent ctDNA− status post-cystectomy (through 12 months) using data from surveillance arm of the global, double-blind, randomized Phase III IMvigor011 study. 
11:00 PM
Duration 1hr Dallas, USA
Disease-free survival and overall survival in patients with high-risk muscle-invasive bladder cancer who have persistent circulating tumor DNA-negative biomarker status post-cystectomy: IMvigor011 study surveillance analysis
E Goluboff, Y Shi, Z J Assaf, V Degaonkar, T. Powles; J. Bellmunt; J. Bjergaard Jensen; M. Gross-Goupil; S. Bracarda; J. Gschwend; A. Kann; L. Makaroff; H. Nishiyama; D. Castellano, S Jiang, J H Ku, S H Park, B M Gonzalez, M Maruzzo, D Yi, Y Urun, R M Barrera, C Buttigliero

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar